Lindahl acts as legal advisor when CellaVision AB (publ) (”CellaVision”) acquires the Singaporean company Clearbridge Biophotonics Pte. Ltd. (the ”Company”) and thereby exclusive rights to a patent portfolio on Fourier Ptychographic Microscopy, a novel microscopy technology.
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. CellaVision’s share is listed on the Nasdaq Stockholm, Mid Cap list.
The microscopy technology which CellaVision, through the acquisition, gets access to has been developed at California Institute of Technology and is a method for creating high-resolution images with low-magnification optics. This enables images of large areas to be acquired at high resolution with higher speed than using conventional digital microscopy. CellaVision believes that the Fourier Ptychography Microscopy technology has potential to - in the future - be used to develop future automated microscopes, with applications in both hematology and adjacent areas.
Lindahl’s team consisted of Johan Herrström and Pernilla Skoglösa (M&A).
